Plasma dimethylglycine and risk of incident acute myocardial infarction in patients with stable angina pectoris

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 33, Issue 8, 2013, Pages 2041-2048

  Tveitevåg Svingen, Gard Frodahl ^a   Ueland, Per Magne ^a   Pedersen, Eva Kristine Ringdal ^a   Schartum Hansen, Hall ^b   Seifert, Reinhard ^b   Ebbing, Marta ^c   Løland, Kjetil Halvorsen ^a   Tell, Grethe S ^a   Nygård, Ottar ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

Author keywords

Acute myocardial infarction; Angina pectoris; Biological markers; Lipids; Smoking

Indexed keywords

APOLIPOPROTEIN B100; DIMETHYLGLYCINE; TRIACYLGLYCEROL;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; FEMALE; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; STABLE ANGINA PECTORIS; TRIACYLGLYCEROL BLOOD LEVEL;

ACUTE MYOCARDIAL INFARCTION; ANGINA PECTORIS; BIOLOGICAL MARKERS; LIPIDS; SMOKING;

ADULT; AGED; ANGINA, STABLE; BIOLOGICAL MARKERS; ENERGY METABOLISM; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; LIPID METABOLISM; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; SARCOSINE; THROMBOSIS;

EID: 84881026749     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.113.301714     Document Type: Article

References (36)

1. Ueland PM. Choline and betaine in health and disease. J Inherit Metab Dis. 2011;34: 3-15.
2. Clarke R, Collins R, Lewington S, et al. Homocysteine Studies C. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA. 2002;288: 2015-2022.
3. Lever M, George PM, Elmslie JL, Atkinson W, Slow S, Molyneux SL, Troughton RW, Richards AM, Frampton CM, Chambers ST. Betaine and secondary events in an acute coronary syndrome cohort. PLoS One. 2012;7:e37883.
4. Clarke R, Halsey J, Lewington S, et al; B-Vitamin Treatment Trialists' Collaboration. Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: meta-analysis of 8 randomized trials involving 37 485 individuals. Arch Intern Med. 2010;170: 1622-1631.
5. Pajares MA, Pérez-Sala D. Betaine homocysteine S-methyltransferase: just a regulator of homocysteine metabolism? Cell Mol Life Sci. 2006;63 : 2792-2803.
6. Lever M, George PM, Dellow WJ, Scott RS, Chambers ST. Homocysteine, glycine betaine, and N,N-dimethylglycine in patients attending a lipid clinic. Metabolism. 2005;54: 1-14.
7. Tibbetts AS, Appling DR. Compartmentalization of mammalian folatemediated one-carbon metabolism. Annu Rev Nutr. 2010;30: 57-81.
8. Allen RH, Stabler SP, Lindenbaum J. Serum betaine, N,N-dimethylglycine and N-methylglycine levels in patients with cobalamin and folate deficiency and related inborn errors of metabolism. Metabolism. 1993;42: 1448-1460.
9. Schwab U, Alfthan G, Aro A, Uusitupa M. Long-term effect of betaine on risk factors associated with the metabolic syndrome in healthy subjects. Eur J Clin Nutr. 2011;65: 70-76.
10. Ntaios G, Savopoulos C, Chatzopoulos S, Mikhailidis D, Hatzitolios A. Iatrogenic hyperhomocysteinemia in patients with metabolic syndrome: a systematic review and metaanalysis. Atherosclerosis. 2011;214: 11-19.
11. Sheikh K, Camejo G, Lanne B, Halvarsson T, Landergren MR, Oakes ND. Beyond lipids, pharmacological PPARalpha activation has important effects on amino acid metabolism as studied in the rat. Am J Physiol Endocrinol Metab. 2007;292:E1157-E1165.
12. Sparks JD, Collins HL, Chirieac DV, Cianci J, Jokinen J, Sowden MP, Galloway CA, Sparks CE. Hepatic very-low-density lipoprotein and apolipoprotein B production are increased following in vivo induction of betaine-homocysteine S-methyltransferase. Biochem J. 2006;395: 363-371.
13. Olthof MR, van Vliet T, Verhoef P, Zock PL, Katan MB. Effect of homocysteine-lowering nutrients on blood lipids: results from four randomised, placebo-controlled studies in healthy humans. PLoS Med. 2005;2:e135.
14. Fredriksen A, Meyer K, Ueland PM, Vollset SE, Grotmol T, Schneede J. Large-scale population-based metabolic phenotyping of thirteen genetic polymorphisms related to one-carbon metabolism. Hum Mutat. 2007;28: 856-865.
15. Weisberg IS, Park E, Ballman KV, Berger P, Nunn M, Suh DS, Breksa AP 3rd, Garrow TA, Rozen R. Investigations of a common genetic variant in betaine-homocysteine methyltransferase (BHMT) in coronary artery disease. Atherosclerosis. 2003;167: 205-214.
16. Gallo V, Egger M, McCormack V, Farmer PB, Ioannidis JP, Kirsch-Volders M, Matullo G, Phillips DH, Schoket B, Stromberg U, Vermeulen R, Wild C, Porta M, Vineis P; STROBE Statement. STrengthening the Reporting of OBservational studies in Epidemiology-Molecular Epidemiology (STROBE-ME): an extension of the STROBE Statement. PLoS Med. 2011;8:e1001117.
17. Graffelman J, Camarena JM. Graphical tests for Hardy-Weinberg equilibrium based on the ternary plot. Hum Hered. 2008;65: 77-84.
18. Lundberg P, Dudman NP, Kuchel PW, Wilcken DE. 1H NMR determination of urinary betaine in patients with premature vascular disease and mild homocysteinemia. Clin Chem. 1995;41: 275-283.
19. Hasokawa M, Shinohara M, Tsugawa H, Bamba T, Fukusaki E, Nishiumi S, Nishimura K, Yoshida M, Ishida T, Hirata K. Identification of biomarkers of stent restenosis with serum metabolomic profiling using gas chromatography/ mass spectrometry. Circ J. 2012;76: 1864-1873.
20. Singh PR, Lele SS. Folate gene polymorphisms MTR A2756G, MTRR A66G, and BHMT G742A and risk for coronary artery disease: a metaanalysis. Genet Test Mol Biomarkers. 2012;16: 471-475.
21. Holm PI, Ueland PM, Vollset SE, Midttun Ø, Blom HJ, Keijzer MB, den Heijer M. Betaine and folate status as cooperative determinants of plasma homocysteine in humans. Arterioscler Thromb Vasc Biol. 2005;25: 379-385.
22. McGregor DO, Dellow WJ, Lever M, George PM, Robson RA, Chambers ST. Dimethylglycine accumulates in uremia and predicts elevated plasma homocysteine concentrations. Kidney Int. 2001;59: 2267-2272.
23. Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med. 2002;53: 409-435.
24. Kersten S, Mandard S, Escher P, Gonzalez FJ, Tafuri S, Desvergne B, Wahli W. The peroxisome proliferator-activated receptor alpha regulates amino acid metabolism. FASEB J. 2001;15: 1971-1978.
25. Ribet C, Montastier E, Valle C, Bezaire V, Mazzucotelli A, Mairal A, Viguerie N, Langin D. Peroxisome proliferator-activated receptor-alpha control of lipid and glucose metabolism in human white adipocytes. Endocrinology. 2010;151: 123-133.
26. Mannino DM, Mulinare J, Ford ES, Schwartz J. Tobacco smoke exposure and decreased serum and red blood cell folate levels: data from the Third National Health and Nutrition Examination Survey. Nicotine Tob Res. 2003;5: 357-362.
27. Konstantinova SV, Tell GS, Vollset SE, Nygård O, Bleie Ø, Ueland PM. Divergent associations of plasma choline and betaine with components of metabolic syndrome in middle age and elderly men and women. J Nutr. 2008;138: 914-920.
28. Ulvik A, Ebbing M, Hustad S, Midttun Ø, Nygård O, Vollset SE, Bønaa KH, Nordrehaug JE, Nilsen DW, Schirmer H, Ueland PM. Long- and short-term effects of tobacco smoking on circulating concentrations of B vitamins. Clin Chem. 2010;56: 755-763.
29. Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation. 2007;116: 85-97.
30. Wang Z, Klipfell E, Bennett BJ, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011;472: 57-63.
31. Tang WH, Wang Z, Levison BS, Koeth RA, Britt EB, Fu X, Wu Y, Hazen SL. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med. 2013;368: 1575-1584.
32. Strakova J, Gupta S, Kruger WD, Dilger RN, Tryon K, Li L, Garrow TA. Inhibition of betaine-homocysteine S-methyltransferase in rats causes hyperhomocysteinemia and reduces liver cystathionine β-synthase activity and methylation capacity. Nutr Res. 2011;31: 563-571.
33. Roberts R, Stewart AF. Genes and coronary artery disease: where are we? J Am Coll Cardiol. 2012;60: 1715-1721.
34. Pierce BL, Ahsan H, Vanderweele TJ. Power and instrument strength requirements for Mendelian randomization studies using multiple genetic variants. Int J Epidemiol. 2011;40: 740-752.
35. Smith GD, Ebrahim S. 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol. 2003;32: 1-22.
36. Hustad S, Eussen S, Midttun O, Ulvik A, van de Kant PM, Morkrid L, Gislefoss R, Ueland PM. Kinetic modeling of storage effects on biomarkers related to B vitamin status and one-carbon metabolism. Clin Chem. 2012;58:402-410.